Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115741 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von David Tougeron und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France. Electronic address: david.tougeron@chu-poitiers.fr. Hauptthemen laut MEDLINE: Paclitaxel, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Servier.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France. Electronic address: david.tougeron@chu-poitiers.fr.
- Liver and Gastro-intestinal Radiation Oncology unit, Institut du Cancer Provence Avignon Sainte Catherine, Avignon, France.
- Department of Digestive Oncology, Georges Pompidou European Hospital, AP-HP, Université Paris Cité, Paris Cancer Institute CARPEM, Paris, France.
- Fédération Francophone de Cancérologie Digestive, EPICAD INSERM LNC-UMR 1231, Bourgogne Franche-Comté University, Dijon, France.
- Department of Gastroenterology and Digestive Oncology, Saint Nazaire Centre, Saint Nazaire, France.
- Department of Gastroenterology and Digestive Oncology, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France.
Förderung
- Servier
Zitieren
APA
Tougeron, D., Mineur, L., Zaanan, A., Kadi, M., Poisson Ligeza, C., Bourgeois, V., Martin-Babau, J., Fadin, A., Jestin le Tallec, V., Ly Lebrun, V., Dubreuil, O., Khemissa Akouz, F., Thimonier, E., Bouché, O., Lièvre, A., Di Fiore, F., Lecomte, T., Lepage, C., Hautefeuille, V., & PRODIGE 62-FFCD 1701-OESIRI investigators/collaborators (2025). Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115741
Vancouver
Tougeron D, Mineur L, Zaanan A, Kadi M, Poisson Ligeza C, Bourgeois V, et al. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI). European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115741
BibTeX
@article{Tougeron2025,
author = {Tougeron, David and Mineur, Laurent and Zaanan, Aziz and Kadi, Melissa and Poisson Ligeza, Catherine and Bourgeois, Vincent and Martin-Babau, Jérôme and Fadin, Aurélie and Jestin le Tallec, Véronique and Ly Lebrun, Valérie and Dubreuil, Olivier and Khemissa Akouz, Faiza and Thimonier, Elsa and Bouché, Olivier and Lièvre, Astrid and Di Fiore, Frédéric and Lecomte, Thierry and Lepage, Côme and Hautefeuille, Vincent and PRODIGE 62-FFCD 1701-OESIRI investigators/collaborators, PRODIGE 62-FFCD 1701-OESIRI investigators/collaborators},
title = {Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115741}
}
EUVIMED